Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ELAN with free AI briefings, catalyst countdowns, and dilution alerts.

ELAN · Elanco Animal Health Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$465M Cash on Hand
CF+ Cash Runway
Follow ELAN by email Get an email when ELAN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ELAN, unsubscribe in one click. Privacy

📣 What ELAN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

ELAN holds $465M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ELAN files for a raise →

👥 Who Owns ELAN

Insiders 0.2% Institutions (706 holders) 99.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 66,242,260 13.25% 2026-09-30
Dodge & Cox Institution (13G, 5%+) 61,430,997 12.29% 2026-09-30
PRIMECAP MANAGEMENT CO/CA/ Institution (13G, 5%+) 45,840,956 9.17% 2026-03-31
Vanguard Capital Management Institution (13G, 5%+) 26,138,990 5.23% 2026-03-31
Dimensional Fund Advisors LP Institution (13G, 5%+) 25,417,271 5.09% 2026-06-30
Lawrence Erik Kurzius
Director
Insider 188,647 0.04% 2026-08-20
Timothy J Bettington
Officer
Insider 138,911 0.03% 2026-10-15
Robert M VanHimbergen
EVP and CFO · +184 options
Insider 137,516 0.03% 2026-08-07
Michael J Harrington
Director
Insider 131,451 0.03% 2026-08-12
Paul Herendeen
Director
Insider 111,687 0.02% 2026-08-07
Denise Scots-Knight
Director
Insider 105,588 0.02% 2026-05-21
Shiv O'Neill
GC AND CORP SEC
Insider 87,832 0.02% 2026-08-18

Share count 499,827,067 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ELAN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELAN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.